EVKEEZA Lowdown Brochure

Finding support on your EVKEEZA ® (evinacumab-dgnb) journey Once you’ve added EVKEEZA to your treatment plan, and your labs show that it’s working for you, it can inspire you to hold on to your drop in bad cholesterol (LDL-C) from HoFH. This drop in LDL-C is yours, and it’s a result of your commitment and the actions you’ve taken to advance toward your goals.

Why staying on your cholesterol-lowering treatments matters HoFH is a serious condition that begins even before birth and makes the body unable to clear bad cholesterol (LDL-C). This condition runs in your family and is caused by changes, or mutations, in the LDL receptor gene or other related genes. With these mutations, LDL receptors cannot effectively remove LDL from the bloodstream to help keep cholesterol levels in a typical range. You may not be able to control your genetics, but you can take action to control your genetically high cholesterol due to HoFH.

EVKEEZA can build on the results you’ve worked so hard to achieve

EVKEEZA can be an important part of your ongoing treatment plan because it works differently from your other prescribed cholesterol-lowering medications. Each medication plays a role in keeping your LDL-C lower.

EVKEEZA reduced bad cholesterol by nearly 50% after 6 months in adults* and children 5 years and older † when added to other cholesterol-lowering treatments.

A key partner and source of support You may receive EVKEEZA at a different location from where your healthcare provider helps manage your cholesterol. Even if you do, your healthcare provider is still there to support you and answer any questions you may have and can stay updated on your treatments.

Individual results may vary.

IMPORTANT SAFETY INFORMATION (continued) Before receiving EVKEEZA, tell your healthcare provider about all of your medical conditions, including if you: • Are breastfeeding or plan to breastfeed. It is not known if EVKEEZA passes into your breast milk. You and your healthcare provider should decide if you will receive EVKEEZA or breastfeed. *At the beginning of the clinical trial, 65 patients with HoFH were enrolled (43 people for EVKEEZA, 22 people for placebo). Participants’ average treated bad cholesterol at baseline was 255 mg/dL. Patients were also receiving other lipid-lowering treatments, including maximally tolerated statins, ezetimibe, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor antibodies, lomitapide, and lipoprotein apheresis. Patients on EVKEEZA had an average 49% reduction in their bad cholesterol at 6 months compared with placebo. † The clinical trial enrolled 20 patients with HoFH, 14 were evaluated for treatment efficacy. The average treated bad cholesterol at baseline was 264 mg/dL. Patients were also receiving other lipid-lowering treatments, including statins, ezetimibe, lomitapide, and lipoprotein apheresis. Patients on EVKEEZA had an average 48% reduction in their bad cholesterol at 6 months. Stay on EVKEEZA and your other cholesterol-lowering medicines to maintain your LDL-C results These treatments can help lower your LDL-C, but this reduction is not permanent. Since HoFH is a lifelong condition, it’s important to continue managing it with ongoing treatment.

Stay in touch with your healthcare provider to track your LDL-C results over time.

IMPORTANT SAFETY INFORMATION (continued) Before receiving EVKEEZA, tell your healthcare provider about all of your medical conditions, including if you: • Are pregnant or plan to become pregnant. EVKEEZA may harm your unborn baby. Tell your healthcare provider if you become pregnant while using EVKEEZA. People who are able to become pregnant: • Your healthcare provider may do a pregnancy test before you start treatment with EVKEEZA. • You should use an effective method of birth control during treatment and for at least 5 months after the last dose of EVKEEZA. Talk with your healthcare provider about birth control methods that you can use during this time. HoFH=homozygous familial hypercholesterolemia; LDL-C=low-density lipoprotein cholesterol. *This is an estimate based on an analysis of patients enrolled in myRARE ® and receiving EVKEEZA through a specialty pharmacy from February 2021 through March 31, 2024, in which 82% of patients received a shipment 12 months after their initial shipment. Patients who did not receive EVKEEZA through a specialty pharmacy are not included in the analysis.

Please see additional Important Safety Information on following pages and click here for full Prescribing Information, including Patient Information.